ChemTrak names new vice president of research and development
BusinessWire, Wednesday, March 19, 1997 at 08:23
SUNNYVALE, Calif.--(BUSINESS WIRE)--March 19, 1997--ChemTrak
Inc. (NASDAQ:CMTR) has announced the promotion of Subba Rao
Gunupudi, Ph.D. to the position of vice president of research and
development.
Gunupudi, who has been instrumental in the development of
ChemTrak's H.pylori test, will lead the ongoing development of
several new products including the company's new one-step AccuMeter
HIV test.
Since 1966, Gunupudi held the post of Director of Research and
Development at ChemTrak, where he finalized formulations for the
HpChek H.pylori test and for the company's quantitative immunoassay
AccuMeter Theophylline test for respiratory applications.
"Dr. Gunupudi's experience in developing innovative,
instrument-free immunoassays has been critical to development of new
applications for our proprietary technology," said Edward F. Covell,
president and chief executive officer of ChemTrak.
Prior to joining ChemTrak, Gunupudi served as a group leader of
immunoassay development of Genzyme Diagnostics where he developed
several rapid one-step assays.
Gunupudi received his Ph.D. in biochemistry from the Indian
Institute of Science in Bagalore, India. He did his post doctoral
work at Temple University School of Medicine in Philadelphia, where
he also served in many capacities, including Assistant Professor,
Department of Obstetrics and Gynecology.
Currently, ChemTrak's CholesTrak Home Cholesterol Test, the
first-FDA-approved product of its kind, is available internationally
and in most retail pharmacies and mass merchandise outlets in the
United States. ChemTrak has also received marketing clearance for
its single-use, whole blood, physician's office test for
Helicobacter Pylori (H.pylori), the bacterium now recognized as a
contributor to duodenal and peptic ulcers in humans.
While the company awaits final FDA clearance for its Aware home
HIV test system, ChemTrak recently announced the U.S. retail market
entry of ColoCARE, a non-invasive home test to detect the early
warning signs of colorectal disease.
Statements in this release that relate to product performance,
customer acceptance, market conditions and new product plans are
forward-looking statements. Actual results might differ materially
from these statements due to risks and uncertainties -- including
determinations by the FDA, the impact of competitive product and
pricing, and the timely development and acceptance of new products,
and medical market conditions.
CONTACT: Freeman/McCue Public Relations
714/557-3663
or
ChemTrak Inc.
408/773-8156
KEYWORD: CALIFORNIA FN
INDUSTRY KEYWORD: MEDICINE |
